The Medical Sciences Proof-of-Principle (MSc PoP) program, administered by Ontario Centres of Excellence on behalf of Ontario's Ministry of Research & Innovation, is a province-wide initiative for which MaRS Innovation accepts applications from our 15 member institutions.
MaRS Innovation is currently recruiting applications for the July 30, 2015 August 27, 2015 (2 pm) deadline; for submissions to be considered via MI, paperwork must be in byAugust 24, 2015 (4 pm).
We've also learned there will be a second call for MScPoP applications in ...
Xagenic Inc., a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, announced October 15, 2014 that its project in partnership with the University of Toronto was successful in securing funding from Genome Canada under the Genomic Applications Partnership Program (GAPP).
The funding, announced by the Honourable Ed Holder, Minister of State (Science and Technology) and Dr. Pierre Meulien, president and CEO of Genome Canada, is part of 12 selected projects under Genome Canada’s Genomic Applications ...
UTEST among the four U of T entrepreneurship programs to be funded through Ontario's CLA program
The University of Toronto will receive $3,056,000 in funding over two years from the Ontario government to increase its training and support for student entrepreneurship.
The funding is part of the Campus-Linked Accelerator Program (CLA), announced today by Reza Moridi, Ontario’s Minister of Research and Innovation, and Minister of Training, Colleges and Universities.
“Fostering the entrepreneurial spirit among students is a key component of Ontario’s Youth Jobs Strategy, ...
Researchers working in orphan indications, drug delivery devices, big data and other key areas invited to submit a brief Statement of Interest
The MaRS Innovation Industry Access Program (MI-IAP) is a simple, formalized process for marketing early-stage technologies to MI's industry partners: Baxter, LifeLabs (formerly CML Healthcare), GSK, Johnson & Johnson, Pfizer and Merck.
The program's goal is to secure funding for researchers within MI's membership through these collaborative, strategic R&D partnership programs.
First run in November 2013, the MI-IAP allows researchers to easily ...
The University of Toronto Early Stage Technology (UTEST) program was the focus of a recent online article in BetaKit, a Canadian innovation and technology resource.
The article by Joseph Czikk, BetaKit's managing editor, is part of a series on Canada's most promising start-up accelerators and the people who make them successful. Czikk highlights UTEST "as one of the most value-packed programs in the entire country" and credits the calibre of applicants and ideas to the program's requirement to have at least one co-founder ...
Technology developed by Dr. Stuart Berger at UHN is first project funded through partnership
TORONTO, Dec. 11, 2013 - MaRS Innovation, a Centre of Excellence for Commercialization and Research, has announced the first project funded through the Pfizer Inc. and MaRS Innovation strategic partnership.
Dr. Stuart Berger, senior scientist at University Health Network, has developed a potential innovation for the bio-manufacturing sector, which is a rapid-growth area.
This announcement was covered by BetaKit.
His technology generates cell lines with improved protein production and survival properties, important in the ...
Collaboration will advance early-stage technologies and identify high-potential opportunities related to human health
TORONTO, Nov. 25, 2013 - MaRS Innovation (MI), a Centre of Excellence for Commercialization and Research, today announced a new collaboration with Johnson & Johnson Innovation and its affiliate Janssen, Inc., in Canada to advance early-stage technologies related to human health in therapeutics, medical devices, and diagnostics.
This announcement was covered by Biotechnology Focus and the Village Gamer blog.
Through the collaboration, MaRS Innovation and technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will jointly ...
TORONTO, ON (Feb. 19, 2013) – XLV Diagnostics Inc., a start-up company working to commercialize a faster, cheaper and better digital mammography technology, has received a $500,000 investment from FedNor.
Over 600 million women living in developing countries have inadequate access to breast screening for early cancer detection. In the developed world, many radiology departments are replacing traditional film and screen systems with digital technologies. In both cases, better digital mammography technology promises to solve logistical challenges and save money.
XLV’s solution has ...
BOSTON, MA, June 18, 2012 — Together with key partners from Ontario, The Québec Consortium for Drug Discovery (CQDM) is creating a new initiative to fund collaborative life sciences research projects between the two provinces.
A French version of this release is available via CQDM's website.
This initiative is the first notable and concrete realization of the Ontario-Québec Life Sciences Corridor, announced at the 2011 BIO International Convention. It builds upon two previous pilot projects and existing strengths within the two provinces to ...
CQDM invests $1.5 million in two collaborative projects within the Québec/Ontario Life Sciences Corridor
Toronto, December 6, 2011 — The Québec Consortium for Drug Discovery (CQDM) is pleased to announce $1.5 million in funding for two joint Québec/Ontario research projects in biomedical research.
The news was released today at the conference, Connecting Life Sciences Across the Ontario-Québec Corridor, which was held in Toronto. (more…)